Modulation of Mcl-1 sensitizes glioblastoma to TRAIL-induced apoptosis

Measuring apoptosis by microscopy and flow cytometry

(2013) Conor M. Henry et al.   METHODS

Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP

(2012) A Bangert et al.   ONCOGENE

Cisplatin Restores TRAIL Apoptotic Pathway in Glioblastoma-Derived Stem Cells through Up-regulation of DR5 and Down-regulation of c-FLIP

(2011) Lijuan Ding et al.   CANCER INVESTIGATION

Effects of the cyclin-dependent kinase inhibitor R-roscovitine on eosinophil survival and clearance

(2011) N. Farahi et al.   CLINICAL AND EXPERIMENTAL ALLERGY

Modulation of NOXA and MCL-1 as a Strategy for Sensitizing Melanoma Cells to the BH3-Mimetic ABT-737

(2011) K. M. Lucas et al.   CLINICAL CANCER RESEARCH

Bortezomib Primes Glioblastoma, Including Glioblastoma Stem Cells, for TRAIL by Increasing tBid Stability and Mitochondrial Apoptosis

(2011) T. Unterkircher et al.   CLINICAL CANCER RESEARCH

Targeting Mcl-1 for the therapy of cancer

(2011) Bridget A Quinn et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Bortezomib Sensitizes Malignant Human Glioma Cells to TRAIL, Mediated by Inhibition of the NF- B Signaling Pathway

(2011) E. P. Jane et al.   MOLECULAR CANCER THERAPEUTICS

Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage

(2011) Daniel R. Premkumar et al.   MOLECULAR CARCINOGENESIS

Lyapunov exponents and phase diagrams reveal multi-factorial control over TRAIL-induced apoptosis

(2011) B. B. Aldridge et al.   Molecular Systems Biology

Caspase 3–mediated stimulation of tumor cell repopulation during cancer radiotherapy

(2011) Qian Huang et al.   NATURE MEDICINE

Direct In Vivo Evidence for Tumor Propagation by Glioblastoma Cancer Stem Cells

(2011) Justin D. Lathia et al.   PLoS One

3D tumour models: novel in vitro approaches to cancer studies

(2011) Agata Nyga et al.   Journal of Cell Communication and Signaling

Selective involvement of BH3-only proteins and differential targets of Noxa in diverse apoptotic pathways

(2010) L Zhang et al.   CELL DEATH AND DIFFERENTIATION

The cyclin-dependent kinase inhibitor R-roscovitine down-regulates Mcl-1 to override pro-inflammatory signalling and drive neutrophil apoptosis

(2010) Andrew E. Leitch et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Review: On TRAIL for malignant glioma therapy?

(2010) J. M. A. Kuijlen et al.   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY

Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4+ CD8+ thymocytes

(2010) J. A. Ryan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The CDK inhibitor, R-roscovitine, promotes eosinophil apoptosis by down-regulation of Mcl-1

(2009) Rodger Duffin et al.   FEBS LETTERS

Identification of survival-related genes of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma multiforme

(2008) Yolanda Ruano et al.   CANCER

Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism

(2008) Gustavo Ortiz-Ferrón et al.   CELL RESEARCH

Upregulation of DR5 by proteasome inhibitors potently sensitizes glioma cells to TRAIL-induced apoptosis

(2008) Holger Hetschko et al.   FEBS Journal

Stem Cell–Related “Self-Renewal” Signature and High Epidermal Growth Factor Receptor Expression Associated With Resistance to Concomitant Chemoradiotherapy in Glioblastoma

(2008) Anastasia Murat et al.   JOURNAL OF CLINICAL ONCOLOGY

Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins

(2008) K E Tagscherer et al.   ONCOGENE

Age-dependent pharmacokinetics and effect of roscovitine on Cdk5 and Erk1/2 in the rat brain

(2008) H SALLAM et al.   PHARMACOLOGICAL RESEARCH